SG Americas Securities LLC Sells 26,166 Shares of Insulet Co. (NASDAQ:PODD)

SG Americas Securities LLC trimmed its stake in shares of Insulet Co. (NASDAQ:PODDFree Report) by 79.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,582 shares of the medical instruments supplier’s stock after selling 26,166 shares during the quarter. SG Americas Securities LLC’s holdings in Insulet were worth $1,428,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. HighTower Advisors LLC grew its position in Insulet by 1.4% during the 1st quarter. HighTower Advisors LLC now owns 2,968 shares of the medical instruments supplier’s stock worth $948,000 after acquiring an additional 41 shares during the last quarter. Moneta Group Investment Advisors LLC grew its position in Insulet by 7.7% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $214,000 after acquiring an additional 53 shares during the last quarter. Capula Management Ltd grew its position in Insulet by 7.4% during the 2nd quarter. Capula Management Ltd now owns 920 shares of the medical instruments supplier’s stock worth $265,000 after acquiring an additional 63 shares during the last quarter. Fund Management at Engine No. 1 LLC grew its position in shares of Insulet by 7.7% in the 2nd quarter. Fund Management at Engine No. 1 LLC now owns 907 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 65 shares during the last quarter. Finally, Cresset Asset Management LLC grew its position in shares of Insulet by 6.6% in the 1st quarter. Cresset Asset Management LLC now owns 1,102 shares of the medical instruments supplier’s stock worth $293,000 after buying an additional 68 shares during the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Robert W. Baird upgraded Insulet from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $180.00 to $238.00 in a research report on Thursday, December 21st. Stifel Nicolaus lifted their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Morgan Stanley upgraded Insulet from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $185.00 to $234.00 in a research note on Monday, December 4th. Barclays lowered their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research note on Monday, February 26th. Finally, Piper Sandler lowered their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $250.33.

Read Our Latest Stock Analysis on Insulet

Insulet Stock Performance

NASDAQ:PODD opened at $171.40 on Friday. The stock has a 50-day simple moving average of $182.15 and a two-hundred day simple moving average of $178.32. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The firm has a market capitalization of $11.99 billion, a PE ratio of 58.90, a P/E/G ratio of 3.04 and a beta of 0.98.

Insulet (NASDAQ:PODDGet Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. During the same quarter in the previous year, the company posted $0.55 earnings per share. Insulet’s revenue for the quarter was up 37.9% on a year-over-year basis. Analysts forecast that Insulet Co. will post 3.08 EPS for the current year.

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Read More

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.